バイオサージェリー市場 – 2030年までの世界予測

本レポートは、バイオサージェリー市場を製品、用途、エンドユーザー、地域の観点から分析しています。また、市場成長に影響を与える要因（推進要因、制約要因、機会、課題など）を分析するとともに、市場リーダーの競争環境の詳細も提供しています。さらに、ミクロ市場の成長傾向を分析し、5つの主要地域（および各地域に所在する各国）における市場セグメントの収益予測も提供しています。

The global biosurgery market is projected to reach USD 21.59 million by 2030 from USD 15.83 million in 2025, at a CAGR of 6.4% during the forecast period.  The biosurgery market is experiencing robust growth, propelled by several key dynamics. A primary driver is the increasing prevalence of chronic conditions that necessitate surgical interventions, alongside a rise in severe traumatic injuries. As these incidents become more common, there is a corresponding uptick in the volume of elective surgical procedures, subsequently fueling the demand for biosurgical products. Moreover, the escalating need for efficient blood loss management and the enhanced availability of advanced biosurgical technologies further support market expansion. However, this growth trajectory faces challenges, including the high cost associated with biosurgery products, a shortage of adequately skilled professionals, and a stringent regulatory environment, all of which are anticipated to hinder the market’s progress over the forecast period.

世界のバイオサージェリー市場は、2025年の1,583万米ドルから2030年には2,159万米ドルに達し、予測期間中に6.4％のCAGRで成長すると予測されています。バイオサージェリー市場は、いくつかの重要な原動力に支えられ、堅調な成長を遂げています。主な要因は、外科的介入を必要とする慢性疾患の罹患率の増加と、重度の外傷の増加です。これらの事故がより一般的になるにつれて、選択的外科手術の件数もそれに応じて増加し、結果としてバイオサージェリー製品の需要が高まっています。さらに、効率的な失血管理の必要性の高まりと、高度なバイオサージェリー技術の利用可能性の向上が、市場拡大をさらに後押ししています。しかし、この成長軌道は、バイオサージェリー製品に関連する高コスト、適切なスキルを持つ専門家の不足、厳格な規制環境などの課題に直面しており、これらはすべて、予測期間中の市場の進歩を妨げると予想されます。

The demineralized bone matrix subsegment, by bone graft substitutes, held the largest market share in 2024.

Based on product, the biosurgery market is divided into bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. In 2024, the bone graft substitute market was predominantly led by the demineralized bone matrix (DBM) segment, which is recognized for its dual osteoconductive and osteoinductive properties, thereby facilitating effective bone regeneration. Within the broader category of bone graft substitutes—which includes synthetic grafts, bone morphogenetic proteins (BMPs), and other alternatives—DBM has emerged as the most significant player in the biosurgery sector. DBM is extensively employed in various orthopedic procedures, such as spinal fusion and hip & knee replacements, owing to its enhanced clinical efficacy in promoting bone healing. Its versatility is further accentuated by its availability in multiple forms, including pastes, putty, sheets, and flexible fragments, allowing for tailored surgical applications. The process of creating DBM involves the removal of inorganic minerals from allograft bones, which unveils BMPs that actively stimulate osteogenesis. This characteristic positions DBM as a reliable and biologically active substitute for autografts. Furthermore, implementing terminal sterilization techniques, such as gamma irradiation and electron-beam sterilization, ensures the safety and integrity of the product. The sustained preference of surgeons for DBM as a safe, effective, and accessible graft substitute continues to reinforce its leading status within this market segment.

The ambulatory surgical centers of the biosurgery end user market are expected to command the highest CAGR during the study period.

The biosurgery market, based on end users, is divided into ambulatory surgical centers (ASCs), hospitals, clinics, and other end users. The ambulatory surgical centers (ASCs) segment is anticipated to lead growth in the biosurgery market throughout the forecast period. This expansion is underpinned by an increasing demand for cost-effective, efficient, and minimally invasive surgical options. ASCs present an economically viable alternative to traditional hospitals while upholding high standards for surgical safety and clinical outcomes, making them increasingly appealing to patients and healthcare practitioners. These centers are optimally equipped to perform various outpatient procedures, including orthopedic, ophthalmic, cosmetic, and general surgeries. In these settings, biosurgical products such as sealants, hemostats, and adhesion barriers are critical in enhancing surgical precision and promoting patient recovery. Advancements in surgical techniques, anesthesia, and biosurgical technologies accelerate the ongoing transition of surgical volumes from inpatient environments to outpatient facilities. Factors such as rising healthcare expenditures, advantageous reimbursement policies for outpatient procedures, and reduced patient recovery times are further driving the growth of ASCs. As patient preferences increasingly lean toward expedited, same-day procedures with a minimized risk of hospital-acquired infections, the demand for biosurgical solutions in ASCs is projected to escalate, thus propelling rapid growth in this segment.

In 2024, the North America region accounted for the largest share in the biosurgery market.

The global biosurgery market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North American region is projected to maintain the largest share of the global biosurgery market, attributable to its sophisticated healthcare infrastructure, elevated surgical rates, and the concentration of prominent industry players. This region has experienced notable increases in cosmetic and reconstructive surgeries and a marked rise in orthopedic procedures. According to Discovery ABA, approximately 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States in 2022, reflecting a 19% increase in cosmetic surgeries compared to 2019. Furthermore, the 2022 data from the American Joint Replacement Registry (AJRR) highlights over 2.8 million hip and knee procedures conducted across all 50 states and the District of Columbia, underscoring the significant demand for biosurgery products in joint replacement and orthopedic applications. Key drivers for this market expansion include a growing geriatric population, a high incidence of chronic diseases, and an increasing volume of surgical interventions necessitating advanced hemostatic agents, sealants, and materials for soft tissue repair. Coupled with favorable reimbursement frameworks, heightened patient awareness, and substantial R&D investments from leading companies such as Johnson & Johnson, Baxter, and Stryker, North America is solidifying its position as the most dominant and mature biosurgery market globally.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
• By Designation: C-level- 50%, Director level- 30%, and Others- 20%
• By Region: North America- 30%, Europe- 25%, Asia Pacific- 20%, Latin America- 15%, and Middle East & Africa- 10%.

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The players operating in the biosurgery market include Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton, Dickinson and Company (BD) (US), B. Braun Melsungen AG (Germany), Stryker (US), Integra Lifesciences Holdings Corporation (US),  CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew PLC (UK), Tissue Regenix (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Advanced Medical Solutions Group PLC (UK), BioCer Entwicklungs-GmbH  (Germany), and Hannox International Corp. (Taiwan)

Research Coverage

This report studies the biosurgery market based on product, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets concerning their growth trends. It forecasts the revenue of the market segments concerning five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (increasing volume of surgeries and growing prevalence of severe trauma injuries, strong focus on R&D leading to launch of technologically advanced products, and rising need for effective blood loss management in patients), restraints (high price of biosurgery products and rising cost of surgical procedures), opportunities (increasing use of combination materials for enhancing product efficacy, rising adoption of advanced biosurgery products in emerging markets, and growing adoption of adhesive dentistry procedures), challenges (stringent regulatory framework and requirement of skilled personnel for the effective use of biosurgery products)
• Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the biosurgery market
• Product Development/Innovation: Comprehensive understanding of the forthcoming trends, R&D initiatives, and product launches within the biosurgery market
• Market Development: Complete knowledge about profitable developing regions
• Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the biosurgery industry help to diversify the market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton Dickinson and Company (BD) (US), B. Braun SE (Germany), Stryker (US), Integra LifeSciences Holdings Corporation (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), and others.

Table of Contents

1               INTRODUCTION              36

1.1           STUDY OBJECTIVES       36

1.2           MARKET DEFINITION   36

1.3           STUDY SCOPE   37

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 37

1.3.2        INCLUSIONS & EXCLUSIONS       38

1.3.3        YEARS CONSIDERED      39

1.3.4        CURRENCY CONSIDERED            40

1.4           STAKEHOLDERS               40

1.5           SUMMARY OF CHANGES               41

2               RESEARCH METHODOLOGY       42

2.1           RESEARCH DATA              42

2.1.1        SECONDARY DATA          42

2.1.1.1    Key objectives of secondary research                 43

2.1.1.2    List of key secondary sources              43

2.1.1.3    Key data from secondary sources       44

2.1.2        PRIMARY DATA 44

2.1.2.1    Key objectives of primary research    45

2.1.2.2    Key data from primary sources           46

2.1.2.3    Key industry insights           47

2.2           MARKET SIZE ESTIMATION         48

2.2.1        SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)                 48

2.2.2        TOP-DOWN APPROACH                49

2.2.3        COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS      49

2.2.4        GROWTH FORECAST      49

2.3           DATA TRIANGULATION                52

2.4           MARKET RANKING ANALYSIS     52

2.5           STUDY ASSUMPTIONS  53

2.6           RESEARCH LIMITATIONS             53

2.6.1        METHODOLOGY-RELATED LIMITATIONS           53

2.6.2        SCOPE-RELATED LIMITATIONS                 53

2.7           RISK ANALYSIS  54

3               EXECUTIVE SUMMARY  55

4               PREMIUM INSIGHTS       59

4.1           BIOSURGERY MARKET OVERVIEW           59

4.2           NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY AND END USER 60

4.3           GEOGRAPHIC SNAPSHOT OF BIOSURGERY MARKET                 61

4.4           REGIONAL MIX: BIOSURGERY MARKET, 2025–2030 (USD MILLION)            61

4.5           BIOSURGERY MARKET: EMERGING VS. DEVELOPED MARKETS,

2025 VS. 2030 (USD MILLION)      62

5               MARKET OVERVIEW       63

5.1           INTRODUCTION              63

5.2           MARKET DYNAMICS       63

5.2.1        DRIVERS               64

5.2.1.1    Increasing volume of surgeries and growing prevalence of severe trauma injuries      64

5.2.1.2    Rising need for effective blood loss management            64

5.2.2        RESTRAINTS      64

5.2.2.1    High price of biosurgery products and surgical procedures                 64

5.2.3        OPPORTUNITIES              65

5.2.3.1    Rising use of combination materials for enhancing product efficacy   65

5.2.3.2    Growing adoption of adhesive dentistry procedures       65

5.2.4        CHALLENGES    65

5.2.4.1    Stringent regulatory framework         65

5.2.4.2    Scarcity of skilled personnel for effective use of biosurgery products 66

5.3           TECHNOLOGY ANALYSIS             66

5.3.1        KEY TECHNOLOGIES     66

5.3.1.1    Hemostatic & sealant biomaterial technology  66

5.3.1.2    Tissue engineering & regenerative medicine technology                 67

5.3.2        COMPLEMENTARY TECHNOLOGIES       67

5.3.2.1    Surgical imaging & navigation technology        67

5.3.2.2    Sterilization & preservation technology            67

5.3.3        ADJACENT TECHNOLOGIES       68

5.3.3.1    3D printing technology       68

5.3.3.2    Minimally invasive technology            68

5.4           INDUSTRY TRENDS         68

5.4.1        GROWING PREFERENCE FOR GELATIN-BASED ADHESIVES &

HYDROGELS IN SURGICAL PROCEDURES             68

5.4.2        USE OF NANOTECHNOLOGY FOR DEVELOPING NEXT-GENERATION ADHESIVES            69

5.5           VALUE CHAIN ANALYSIS               69

5.6           ECOSYSTEM ANALYSIS  70

5.7           SUPPLY CHAIN ANALYSIS             71

5.8           TRADE ANALYSIS             72

5.8.1        IMPORT DATA FOR HS CODE 300610, 2019–2024  72

5.8.2        EXPORT DATA FOR HS CODE 300610, 2019–2024  72

5.9           PORTER’S FIVE FORCES ANALYSIS           73

5.9.1        THREAT OF NEW ENTRANTS      74

5.9.2        THREAT OF SUBSTITUTES          74

5.9.3        BARGAINING POWER OF BUYERS             75

5.9.4        BARGAINING POWER OF SUPPLIERS       75

5.9.5        INTENSITY OF COMPETITIVE RIVALRY 75

5.10         KEY STAKEHOLDERS & BUYING CRITERIA            75

5.10.1      KEY STAKEHOLDERS IN BUYING PROCESS           75

5.10.2      KEY BUYING CRITERIA  76

5.11         REGULATORY ANALYSIS               77

5.11.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             78

5.11.2      REGULATORY ANALYSIS               80

5.11.2.1  North America      80

5.11.2.1.1                US           80

5.11.2.1.2                Canada   80

5.11.2.2  Europe   81

5.11.2.3  Asia Pacific            81

5.11.2.4  Latin America       82

5.11.2.5  Middle East & Africa            82

5.12         PATENT ANALYSIS          82

5.12.1      INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS            84

5.13         PRICING ANALYSIS          84

5.13.1      AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS,

BY KEY PLAYER, 2022–2024            84

5.13.2      AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS,

BY REGION, 2022–2024    85

5.14         KEY CONFERENCES & EVENTS, 2025–2026              86

5.15         ADJACENT MARKET ANALYSIS  87

5.15.1      ADHESION BARRIERS MARKET  87

5.16         UNMET NEEDS/END-USER EXPECTATIONS         88

5.17         TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            89

5.18         INVESTMENT & FUNDING SCENARIO     89

5.19         IMPACT OF AI/GEN AI ON BIOSURGERY MARKET                 90

5.20         IMPACT OF 2025 US TARIFF ON BIOSURGERY MARKET                 91

5.20.1      INTRODUCTION              91

5.20.2      KEY TARIFF RATES          92

5.20.3      PRICE IMPACT ANALYSIS             93

5.20.4      IMPACT ON COUNTRIES/REGIONS         93

5.20.4.1  North America      93

5.20.4.1.1                US           93

5.20.4.2  Europe   94

5.20.4.3  Asia Pacific            94

5.20.5      IMPACT ON END-USE INDUSTRIES          94

6               BIOSURGERY MARKET, BY PRODUCT     95

6.1           INTRODUCTION              96

6.2           BONE-GRAFT SUBSTITUTES       97

6.2.1        DEMINERALIZED BONE MATRIX               98

6.2.1.1    Rising volume of spinal fusion, joint reconstruction, and replacement surgeries to drive segment            98

6.2.2        SYNTHETIC BONE GRAFTS          100

6.2.2.1    High compressive strength, osteoconductive properties, and minimal risk of disease transmission to fuel segment growth        100

6.2.3        BONE MORPHOGENETIC PROTEINS       102

6.2.3.1    Increasing prevalence of spinal deformities, disc degeneration, trauma, and sport-related injuries to propel segment growth       102

6.2.4        OTHER BONE-GRAFT SUBSTITUTES       103

6.3           SURGICAL SEALANTS & ADHESIVES        105

6.3.1        NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES         107

6.3.1.1    Natural/Biological surgical sealants & adhesives, by type                 108

6.3.1.1.1 Fibrin-based sealants & adhesives     109

6.3.1.1.1.1              Biocompatibility, biodegradability, and effectiveness in achieving hemostasis to augment segment growth          109

6.3.1.1.2 Collagen-based sealants & adhesives 111

6.3.1.1.2.1              Low-cost and reduced risk of disease transmission to promote adoption of collagen-based sealants & adhesives             111

6.3.1.1.3 Gelatin-based sealants & adhesives   113

6.3.1.1.3.1              High elasticity, strong adhesive properties, and versatility in soft tissue applications to boost segment growth      113

6.3.1.1.4 Albumin-based sealants & adhesives 115

6.3.1.1.4.1              Increasing adoption in cardiovascular and cardiothoracic procedures to fuel market growth            115

6.3.1.1.5 Other natural/biological surgical sealants & adhesives  116

6.3.1.2    Natural/biological surgical sealants & adhesives, by origin                 118

6.3.1.2.1 Animal-based sealants & adhesives   118

6.3.1.2.1.1              Ease of usage, better flexibility, and greater strength to boost adoption in medical applications             118

6.3.1.2.2 Human blood-based sealants & adhesives        119

6.3.1.2.2.1              Human blood-based sealants to be used in final stage of clotting cascade for local and diffused hemorrhages       119

6.3.2        SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES         120

6.3.2.1    PEG hydrogel-based sealants & adhesives       123

6.3.2.1.1 Rapid sealing abilities of PEG hydrogels to drive adoption in spinal surgeries     123

6.3.2.2    Cyanoacrylate-based sealants & adhesives       125

6.3.2.2.1 Cyanoacrylate-based sealants to be preferred in dermatology and plastic surgeries    125

6.3.2.3    Urethane-based sealants & adhesives                126

6.3.2.3.1 Favorable thermostable property at body temperature without hemolytic behavior to drive segment 126

6.3.2.4    Other synthetic & semi-synthetic surgical sealants & adhesives                 128

6.4           ADHESION BARRIERS     129

6.4.1        SYNTHETIC ADHESION BARRIERS            131

6.4.1.1    Hyaluronic acid-based adhesion barriers          133

6.4.1.1.1 Rising gynecological and abdominal surgeries to fuel adoption                 133

6.4.1.2    Regenerated cellulose-based adhesion barriers                134

6.4.1.2.1 Increasing number of C-section surgeries to boost adoption of regenerated cellulose-based adhesion barriers 134

6.4.1.3    PEG-based adhesion barriers             136

6.4.1.3.1 Rising number of peritoneal and abdominal surgeries to drive demand  136

6.4.1.4    Other synthetic adhesion barriers     137

6.4.2        NATURAL ADHESION BARRIERS                138

6.4.2.1    Collagen & protein adhesion barriers                139

6.4.2.1.1 Weak antigenicity, high biocompatibility, non-toxicity, and biodegradability to propel segment growth      139

6.4.2.2    Fibrin-based adhesion barriers           140

6.4.2.2.1 Increasing applications in laparotomy procedures to spur segment growth    140

6.5           STAPLE-LINE REINFORCEMENT AGENTS              142

6.5.1        RISING VOLUME OF COMPLEX SURGICAL PROCEDURRES TO DRIVE MARKET         142

6.6           SOFT-TISSUE ATTACHMENTS    143

6.6.1        SYNTHETIC MESHES      145

6.6.1.1    Increasing demand for safe and cost-effective soft tissue reinforcement to drive segment         145

6.6.2        BIOLOGICAL MESHES    146

6.6.2.1    Allografts                148

6.6.2.1.1 Rising cancer incidence and reconstructive surgeries to increase adoption of allografts in biosurgical procedures              148

6.6.2.2    Xenografts              149

6.6.2.2.1 High availability and size versatility to drive segmental growth                 149

6.7           HEMOSTATIC AGENTS  150

6.7.1        THROMBIN-BASED HEMOSTATIC AGENTS          152

6.7.1.1    Rising demand for safer and fast-acting clotting agents to drive growth of thrombin-based hemostats                152

6.7.2        OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS  154

6.7.2.1    Rising adoption of plant-based and absorbable hemostats to propel segment growth        154

6.7.3        COMBINATION HEMOSTATIC AGENTS 155

6.7.3.1    Superior efficacy in complex bleeding control to drive adoption of combination hemostatic agents globally       155

7               BIOSURGERY MARKET, BY APPLICATION             157

7.1           INTRODUCTION              158

7.2           ORTHOPEDIC SURGERY                158

7.2.1        INCREASING INCIDENCE OF SPORTS INJURIES AND GROWING PREVALENCE OF OSTEOPOROSIS TO PROPEL MARKET GROWTH          158

7.3           GENERAL SURGERY        160

7.3.1        HIGH GERIATRIC POPULATION AND INCREASED PREVALENCE OF OBESITY TO FUEL DEMAND FOR BARIATRIC INTERVENTIONS              160

7.4           NEUROLOGICAL SURGERY          162

7.4.1        GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO AUGMENT MARKET GROWTH   162

7.5           CARDIOVASCULAR SURGERY     163

7.5.1        BIOSURGERY PRODUCTS TO REPLACE CONVENTIONAL SUTURE-BASED METHODS IN CARDIOVASCULAR PROCEDURES                 163

7.6           RECONSTRUCTIVE SURGERY     165

7.6.1        INCREASING FACIAL COSMETIC SURGERIES AND BREAST RECONSTRUCTION PROCEDURES TO PROPEL MARKET GROWTH             165

7.7           GYNECOLOGICAL SURGERY       166

7.7.1        COMPLEXITY OF GYNECOLOGICAL PROCEDURES TO FUEL DEMAND FOR ADVANCED BIOSURGICAL PRODUCTS                 166

7.8           UROLOGICAL SURGERY                168

7.8.1        USE OF BIOSURGERY PRODUCTS IN COMPLEX RECONSTRUCTIVE UROLOGICAL SURGERIES TO STIMULATE SEGMENT GROWTH       168

7.9           THORACIC SURGERY     169

7.9.1        RISING INCIDENCE OF PULMONARY CHRONIC DISEASES TO SPUR MARKET GROWTH  169

7.10         OTHER APPLICATIONS 171

8               BIOSURGERY MARKET, BY END USER     173

8.1           INTRODUCTION              174

8.2           HOSPITALS         174

8.2.1        RISING NUMBER OF REIMBURSED INPATIENT PROCEDURES TO DRIVE POPULARITY OF HOSPITALS FOR SURGERIES         174

8.3           CLINICS                176

8.3.1        QUICKER CONSULTATION SERVICES AND MINIMAL PATIENT STAYS TO FAVOR MARKET GROWTH  176

8.4           AMBULATORY SURGICAL CENTERS        177

8.4.1        RISING DEMAND FOR COST-EFFECTIVE SAME-DAY SURGERIES TO AUGMENT MARKET GROWTH    177

8.5           OTHER END USERS         178

9               BIOSURGERY MARKET, BY REGION         180

9.1           INTRODUCTION              181

9.2           NORTH AMERICA             182

9.2.1        MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 182

9.2.2        US           189

9.2.2.1    US to dominate North American biosurgery market during forecast period      189

9.2.3        CANADA               195

9.2.3.1    Growing prevalence of chronic diseases to drive market                 195

9.3           EUROPE               201

9.3.1        MACROECONOMIC OUTLOOK FOR EUROPE      207

9.3.2        GERMANY           207

9.3.2.1    Robust healthcare investments and improved infrastructure to support adoption of advanced surgical technologies       207

9.3.3        UK          213

9.3.3.1    Rise in popularity of cosmetic and reconstructive surgeries to fuel market growth       213

9.3.4        FRANCE                219

9.3.4.1    Presence of well-established healthcare system and high geriatric population to boost market growth    219

9.3.5        ITALY    225

9.3.5.1    Increasing surgical volume to fuel market growth           225

9.3.6        SPAIN    231

9.3.6.1    Rising surgical demand to boost need for biosurgery products                 231

9.3.7        REST OF EUROPE             237

9.4           ASIA PACIFIC     243

9.4.1        MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 243

9.4.2        CHINA  251

9.4.2.1    Increasing number of domestic biosurgery and medical device manufacturers to aid market growth 251

9.4.3        INDIA    257

9.4.3.1    Rising healthcare awareness and favorable government support to stimulate market growth 257

9.4.4        JAPAN   263

9.4.4.1    Advanced healthcare system and high geriatric population to spur market growth       263

9.4.5        SOUTH KOREA  269

9.4.5.1    Rising number of cosmetic surgeries and growing adoption of innovative medical technologies to drive market             269

9.4.6        AUSTRALIA         275

9.4.6.1    Well-established healthcare system and high government medical expenditure to favor market growth  275

9.4.7        REST OF ASIA PACIFIC   281

9.5           LATIN AMERICA                288

9.5.1        MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 288

9.5.2        BRAZIL 294

9.5.2.1    Rapidly aging population and high prevalence of chronic diseases to support market growth    294

9.5.3        MEXICO                300

9.5.3.1    Enhanced focus on medical tourism to drive market      300

9.5.4        REST OF LATIN AMERICA             306

9.6           MIDDLE EAST & AFRICA                313

9.6.1        MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 313

9.6.2        GCC COUNTRIES              319

9.6.2.1    Rising prevalence of chronic diseases to drive market    319

9.6.3        REST OF MIDDLE EAST & AFRICA             325

10            COMPETITIVE LANDSCAPE         332

10.1         INTRODUCTION              332

10.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            332

10.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSURGERY MARKET             332

10.3         REVENUE ANALYSIS, 2020–2024  334

10.4         MARKET SHARE ANALYSIS, 2024                 334

10.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 336

10.5.1      STARS   336

10.5.2      EMERGING LEADERS     336

10.5.3      PERVASIVE PLAYERS      337

10.5.4      PARTICIPANTS 337

10.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         338

10.5.5.1  Company footprint               338

10.5.5.2  Region footprint   339

10.5.5.3  Product footprint  340

10.5.5.4  Application footprint            341

10.5.5.5  End-user footprint                342

10.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        343

10.6.1      PROGRESSIVE COMPANIES         343

10.6.2      RESPONSIVE COMPANIES            343

10.6.3      DYNAMIC COMPANIES  343

10.6.4      STARTING BLOCKS         343

10.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 345

10.6.5.1  Detailed list of key startups/SMEs    345

10.6.5.2  Competitive benchmarking of key startups/SMEs          346

10.7         COMPANY VALUATION & FINANCIAL METRICS 347

10.7.1      FINANCIAL METRICS      347

10.7.2      COMPANY VALUATION 347

10.8         BRAND/PRODUCT COMPARISON             348

10.9         COMPETITIVE SCENARIO             348

10.9.1      PRODUCT LAUNCHES & APPROVALS     348

10.9.2      DEALS  349

11            COMPANY PROFILES      350

11.1         KEY PLAYERS     350

11.1.1      BAXTER                350

11.1.1.1  Business overview 350

11.1.1.2  Products offered   351

11.1.1.3  MnM view              352

11.1.1.3.1                Key strengths        352

11.1.1.3.2                Strategic choices   353

11.1.1.3.3                Weaknesses & competitive threats     353

11.1.2      B. BRAUN SE       354

11.1.2.1  Business overview 354

11.1.2.2  Products offered   355

11.1.2.3  MnM view              356

11.1.2.3.1                Key strengths        356

11.1.2.3.2                Strategic choices   356

11.1.2.3.3                Weaknesses & competitive threats     356

11.1.3      BECTON, DICKINSON AND COMPANY (BD)         357

11.1.3.1  Business overview 357

11.1.3.2  Products offered   358

11.1.3.3  MnM view              360

11.1.3.3.1                Key strengths        360

11.1.3.3.2                Strategic choices   360

11.1.3.3.3                Weaknesses & competitive threats     360

11.1.4      JOHNSON & JOHNSON  361

11.1.4.1  Business overview 361

11.1.4.2  Products offered   362

11.1.4.3  MnM view              363

11.1.4.3.1                Key strengths        363

11.1.4.3.2                Strategic choices   363

11.1.4.3.3                Weaknesses & competitive threats     364

11.1.5      MEDTRONIC      365

11.1.5.1  Business overview 365

11.1.5.2  Products offered   366

11.1.5.3  MnM view              367

11.1.5.3.1                Key strengths        367

11.1.5.3.2                Strategic choices   367

11.1.5.3.3                Weaknesses & competitive threats     368

11.1.6      INTEGRA LIFESCIENCES CORPORATION               369

11.1.6.1  Business overview 369

11.1.6.2  Products offered   370

11.1.7      COMMONWEALTH SERUM LABORATORIES LIMITED (CSL)     372

11.1.7.1  Business overview 372

11.1.7.2  Products offered   373

11.1.8      HEMOSTASIS, LLC            374

11.1.8.1  Business overview 374

11.1.8.2  Products offered   374

11.1.9      PFIZER INC.        375

11.1.9.1  Business overview 375

11.1.9.2  Products offered   376

11.1.10   STRYKER              377

11.1.10.1                 Business overview 377

11.1.10.2                 Products offered   378

11.1.11   ARTIVION, INC. 380

11.1.11.1                 Business overview 380

11.1.11.2                 Products offered   381

11.1.12   ZIMMER BIOMET             383

11.1.12.1                 Business overview 383

11.1.12.2                 Products offered   384

11.1.12.3                 Recent developments           385

11.1.12.3.1             Deals      385

11.1.13   KUROS BIOSCIENCES     386

11.1.13.1                 Business overview 386

11.1.13.2                 Products offered   387

11.1.13.3                 Recent developments           387

11.1.13.3.1             Product approvals 387

11.1.13.3.2             Deals      388

11.1.14   ORTHOFIX MEDICAL INC.            389

11.1.14.1                 Business overview 389

11.1.14.2                 Products offered   390

11.1.14.3                 Recent developments           391

11.1.14.3.1             Product launches  391

11.1.14.3.2             Deals      391

11.1.15   SMITH & NEPHEW           392

11.1.15.1                 Business overview 392

11.1.15.2                 Products offered   393

11.2         OTHER PLAYERS              394

11.2.1      TISSUE REGENIX              394

11.2.2      BETATECH MEDICAL     395

11.2.3      MERIL LIFE SCIENCES PVT. LTD.               396

11.2.4      GLOBUS MEDICAL          397

11.2.5      SAMYANG HOLDINGS CORPORATION   398

11.2.6      AROA BIOSURGERY LIMITED     399

11.2.7      MEYER-HAAKE GMBH    400

11.2.8      ADVANCED MEDICAL SOLUTIONS GROUP PLC 401

11.2.9      BIOCER ENTWICKLUNGS-GMBH               402

11.2.10   WILTROM            403

12            APPENDIX           404

12.1         DISCUSSION GUIDE        404

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                410

12.3         CUSTOMIZATION OPTIONS        412

12.4         RELATED REPORTS         412

12.5         AUTHOR DETAILS           413

LIST OF TABLES

TABLE 1                BIOSURGERY MARKET: INCLUSIONS & EXCLUSIONS      38

TABLE 2                STANDARD CURRENCY CONVERSION RATES                 40

TABLE 3                BIOSURGERY MARKET: STUDY ASSUMPTIONS                 53

TABLE 4                BIOSURGERY MARKET: RISK ANALYSIS  54

TABLE 5                IMPORT DATA FOR HS CODE 300610, BY COUNTRY,

2019–2024 (USD THOUSAND)      72

TABLE 6                EXPORT DATA FOR HS CODE 300610, BY COUNTRY,

2019–2024 (USD THOUSAND)      73

TABLE 7                BIOSURGERY MARKET: PORTER’S FIVE FORCES                 73

TABLE 8                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS         76

TABLE 9                KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS         77

TABLE 10              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 78

TABLE 11              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           78

TABLE 12              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 79

TABLE 13              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 79

TABLE 14              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 80

TABLE 15              AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)                 85

TABLE 16              AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION,

2022–2024 (USD)                85

TABLE 17              BIOSURGERY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS,

JANUARY 2025–DECEMBER 2026 86

TABLE 18              BIOSURGERY MARKET: UNMET NEEDS/END-USER EXPECTATIONS    88

TABLE 19              US-ADJUSTED RECIPROCAL TARIFF RATES                 92

TABLE 20              KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR BIOSURGERY PRODUCTS   93

TABLE 21              BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96

TABLE 22              BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            97

TABLE 23              BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY COUNTRY,

2023–2030 (USD MILLION)            98

TABLE 24              MAJOR DEMINERALIZED BONE MATRIX PRODUCTS AVAILABLE IN MARKET        99

TABLE 25              DEMINERALIZED BONE MATRIX MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 26              MAJOR SYNTHETIC BONE GRAFTS AVAILABLE IN MARKET         101

TABLE 27              SYNTHETIC BONE GRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     101

TABLE 28              MAJOR BONE MORPHOGENETIC PROTEINS AVAILABLE IN MARKET 102

TABLE 29              BONE MORPHOGENETIC PROTEINS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            103

TABLE 30              OTHER BONE-GRAFT SUBSTITUTES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            105

TABLE 31              BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE,

2023–2030 (USD MILLION)            106

TABLE 32              BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY COUNTRY, 2023–2030 (USD MILLION)            107

TABLE 33              NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 108

TABLE 34              NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 109

TABLE 35              MAJOR FIBRIN-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 110

TABLE 36              FIBRIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            111

TABLE 37              MAJOR COLLAGEN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET        112

TABLE 38              COLLEGEN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            113

TABLE 39              MAJOR GELATIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET        114

TABLE 40              GELATIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            114

TABLE 41              MAJOR ALBUMIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET        115

TABLE 42              ALBUMIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            116

TABLE 43              OTHER NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               117

TABLE 44              NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)                 118

TABLE 45              ANIMAL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 46              HUMAN BLOOD-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 47              SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         121

TABLE 48              SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               122

TABLE 49              MAJOR PRODUCTS PEG HYDROGEL-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET              123

TABLE 50              PEG HYROGEL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            124

TABLE 51              MAJOR CYANOACRYLATE-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET        125

TABLE 52              CYANOACRYLATE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            126

TABLE 53              URETHANE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 54              OTHER SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            129

TABLE 55              BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            130

TABLE 56              BIOSURGERY MARKET FOR ADHESION BARRIERS, BY COUNTRY,

2023–2030 (USD MILLION)            130

TABLE 57              SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)                131

TABLE 58              SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            132

TABLE 59              MAJOR HYALURONIC ACID-BASED ADHESION BARRIERS AVAILABLE IN MARKET            133

TABLE 60              HYALURONIC ACID-BASED ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            134

TABLE 61              MAJOR REGENERATED CELLULOSE-BASED ADHESION BARRIERS AVAILABLE IN MARKET    135

TABLE 62              REGENERATED CELLULOSE -BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 135

TABLE 63              MAJOR PEG-BASED ADHESION BARRIERS AVAILABLE IN MARKET 136

TABLE 64              PEG-BASED ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            137

TABLE 65              OTHER SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            138

TABLE 66              NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)                139

TABLE 67              MAJOR COLLAGEN & PROTEIN ADHESION BARRIERS AVAILABLE IN MARKET            139

TABLE 68              COLLAGEN & PROTEIN ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 69              MAJOR FIBRIN-BASED ADHESION BARRIERS AVAILABLE IN MARKET 141

TABLE 70              FIBRIN-BASED ADHESION BARRIERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 71              MAJOR STAPLE-LINE REINFORCEMENT AGENTS AVAILABLE IN MARKET               142

TABLE 72              BIOSURGERY MARKET FOR STAPLE-LINE REINFORCEMENT AGENTS, BY COUNTRY, 2023–2030 (USD MILLION)            143

TABLE 73              BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY TYPE,

2023–2030 (USD MILLION)            144

TABLE 74              BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY COUNTRY,

2023–2030 (USD MILLION)          144

TABLE 75              MAJOR SYNTHETIC MESHES AVAILABLE IN MARKET               145

TABLE 76              SYNTHETIC MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            146

TABLE 77              MAJOR BIOLOGICAL MESHES AVAILABLE IN MARKET               147

TABLE 78              BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)       147

TABLE 79              BIOLOGICAL MESHES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            148

TABLE 80              ALLOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 149

TABLE 81              XENOGRAFTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 150

TABLE 82              MAJOR HEMOSTATIC AGENTS AVAILABLE IN MARKET               151

TABLE 83              BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            151

TABLE 84              BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 85              MAJOR THROMBIN-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET               153

TABLE 86              THROMBIN-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 87              MAJOR OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET  154

TABLE 88              OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               155

TABLE 89              MAJOR COMBINATION HEMOSTATIC AGENTS AVAILABLE IN MARKET 156

TABLE 90             COMBINATION HEMOSTATIC AGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 91              BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       158

TABLE 92              BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 93              BIOSURGERY MARKET FOR GENERAL SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            161

TABLE 94              BIOSURGERY MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            163

TABLE 95              BIOSURGERY MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 96              BIOSURGERY MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 97              BIOSURGERY MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            167

TABLE 98              BIOSURGERY MARKET FOR UROLOGICAL SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 99              BIOSURGERY MARKET FOR THORACIC SURGERY, BY COUNTRY,

2023–2030 (USD MILLION)          170

TABLE 100            BIOSURGERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 101            BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION) 174

TABLE 102            BIOSURGERY MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)     176

TABLE 103            BIOSURGERY MARKET FOR CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)     177

TABLE 104            BIOSURGERY MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)                 178

TABLE 105            BIOSURGERY MARKET FOR OTHER END USERS, BY COUNTRY,

2023–2030 (USD MILLION)            179

TABLE 106            BIOSURGERY MARKET, BY REGION, 2023–2030 (USD MILLION) 182

TABLE 107            NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 108            NORTH AMERICA: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            184

TABLE 109            NORTH AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,

BY TYPE, 2023–2030 (USD MILLION)         184

TABLE 110            NORTH AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            185

TABLE 111            NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       185

TABLE 112            NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       186

TABLE 113            NORTH AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                186

TABLE 114            NORTH AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)                 186

TABLE 115            NORTH AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            187

TABLE 116            NORTH AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            187

TABLE 117            NORTH AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,

BY TYPE, 2023–2030 (USD MILLION)         187

TABLE 118            NORTH AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            188

TABLE 119            NORTH AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)                 188

TABLE 120            NORTH AMERICA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            188

TABLE 121            NORTH AMERICA: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            189

TABLE 122            US: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)       190

TABLE 123            US: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            190

TABLE 124            US: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 191

TABLE 125            US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)            191

TABLE 126            US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    192

TABLE 127            US: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)            192

TABLE 128            US: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            192

TABLE 129            US: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            193

TABLE 130            US: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)         193

TABLE 131            US: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            193

TABLE 132            US: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            194

TABLE 133            US: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            194

TABLE 134            US: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            194

TABLE 135            US: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)       195

TABLE 136            CANADA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            195

TABLE 137            CANADA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            196

TABLE 138            CANADA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 196

TABLE 139            CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         197

TABLE 140            CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    197

TABLE 141            CANADA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       198

TABLE 142            CANADA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            198

TABLE 143            CANADA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            198

TABLE 144            CANADA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            199

TABLE 145            CANADA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 199

TABLE 146            CANADA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                199

TABLE 147            CANADA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            200

TABLE 148            CANADA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              200

TABLE 149            CANADA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            201

TABLE 150            EUROPE: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            201

TABLE 151            EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            202

TABLE 152            EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            202

TABLE 153            EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 203

TABLE 154            EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         203

TABLE 155            EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    204

TABLE 156            EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       204

TABLE 157            EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            204

TABLE 158            EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            205

TABLE 159            EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            205

TABLE 160            EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 205

TABLE 161            EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                206

TABLE 162            EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            206

TABLE 163            EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              206

TABLE 164            EUROPE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            207

TABLE 165            GERMANY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     208

TABLE 166            GERMANY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)                 208

TABLE 167            GERMANY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,

BY TYPE, 2023–2030 (USD MILLION)         208

TABLE 168            GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         209

TABLE 169            GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    209

TABLE 170            GERMANY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       210

TABLE 171            GERMANY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            210

TABLE 172            GERMANY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            210

TABLE 173            GERMANY: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            211

TABLE 174            GERMANY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 211

TABLE 175            GERMANY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                211

TABLE 176            GERMANY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            212

TABLE 177            GERMANY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              212

TABLE 178            GERMANY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)                213

TABLE 179            UK: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)       213

TABLE 180            UK: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            214

TABLE 181            UK: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 214

TABLE 182            UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)            215

TABLE 183            UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    215

TABLE 184            UK: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)            216

TABLE 185            UK: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            216

TABLE 186            UK: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            216

TABLE 187            UK: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            217

TABLE 188            UK: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            217

TABLE 189            UK: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            217

TABLE 190            UK: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            218

TABLE 191            UK: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            218

TABLE 192            UK: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)       219

TABLE 193            FRANCE: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            219

TABLE 194            FRANCE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            220

TABLE 195            FRANCE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 220

TABLE 196            FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         221

TABLE 197            FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    221

TABLE 198            FRANCE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       222

TABLE 199            FRANCE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            222

TABLE 200            FRANCE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            222

TABLE 201            FRANCE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            223

TABLE 202            FRANCE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 223

TABLE 203            FRANCE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                223

TABLE 204            FRANCE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            224

TABLE 205            FRANCE: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              224

TABLE 206            FRANCE: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            225

TABLE 207            ITALY: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            225

TABLE 208            ITALY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            226

TABLE 209            ITALY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 226

TABLE 210            ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         227

TABLE 211            ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    227

TABLE 212            ITALY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       228

TABLE 213            ITALY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            228

TABLE 214            ITALY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            228

TABLE 215          ITALY: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            229

TABLE 216            ITALY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            229

TABLE 217            ITALY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            229

TABLE 218            ITALY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            230

TABLE 219          ITALY: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            230

TABLE 220            ITALY: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            231

TABLE 221            SPAIN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            231

TABLE 222            SPAIN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            232

TABLE 223            SPAIN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 232

TABLE 224            SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         233

TABLE 225            SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    233

TABLE 226            SPAIN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       234

TABLE 227            SPAIN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            234

TABLE 228            SPAIN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            235

TABLE 229          SPAIN: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            235

TABLE 230            SPAIN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            235

TABLE 231            SPAIN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            236

TABLE 232            SPAIN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            236

TABLE 233          SPAIN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            236

TABLE 234            SPAIN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            237

TABLE 235            REST OF EUROPE: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            237

TABLE 236            REST OF EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,

BY TYPE, 2023–2030 (USD MILLION)         238

TABLE 237            REST OF EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            238

TABLE 238            REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       239

TABLE 239            REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       239

TABLE 240            REST OF EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                240

TABLE 241            REST OF EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)                 240

TABLE 242            REST OF EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            241

TABLE 243            REST OF EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            241

TABLE 244            REST OF EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,

BY TYPE, 2023–2030 (USD MILLION)         241

TABLE 245            REST OF EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            242

TABLE 246            REST OF EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)                 242

TABLE 247            REST OF EUROPE: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            242

TABLE 248            REST OF EUROPE: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            243

TABLE 249            ASIA PACIFIC: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     245

TABLE 250            ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     245

TABLE 251            ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)            246

TABLE 252            ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,

BY TYPE, 2023–2030 (USD MILLION)         246

TABLE 253            ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       247

TABLE 254            ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       247

TABLE 255            ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       248

TABLE 256            ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            248

TABLE 257            ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            249

TABLE 258            ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            249

TABLE 259            ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 249

TABLE 260            ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)         250

TABLE 261            ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            250

TABLE 262            ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              250

TABLE 263            ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)                251

TABLE 264            CHINA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            252

TABLE 265            CHINA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            252

TABLE 266            CHINA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 252

TABLE 267            CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         253

TABLE 268            CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    253

TABLE 269            CHINA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       254

TABLE 270            CHINA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            254

TABLE 271            CHINA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            254

TABLE 272            CHINA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            255

TABLE 273            CHINA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            255

TABLE 274          CHINA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            255

TABLE 275            CHINA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            256

TABLE 276            CHINA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              256

TABLE 277            CHINA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            257

TABLE 278            INDIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            257

TABLE 279            INDIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            258

TABLE 280            INDIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 258

TABLE 281            INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         259

TABLE 282            INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    259

TABLE 283            INDIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       260

TABLE 284            INDIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            260

TABLE 285            INDIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            260

TABLE 286          INDIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            261

TABLE 287            INDIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            261

TABLE 288            INDIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            261

TABLE 289            INDIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            262

TABLE 290          INDIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            262

TABLE 291            INDIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            263

TABLE 292            JAPAN: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            263

TABLE 293            JAPAN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            264

TABLE 294            JAPAN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 264

TABLE 295            JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         265

TABLE 296            JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    265

TABLE 297            JAPAN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       266

TABLE 298            JAPAN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            266

TABLE 299            JAPAN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            266

TABLE 300            JAPAN: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            267

TABLE 301            JAPAN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            267

TABLE 302          JAPAN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)            267

TABLE 303            JAPAN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            268

TABLE 304            JAPAN: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              268

TABLE 305            JAPAN: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            269

TABLE 306            SOUTH KOREA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     269

TABLE 307            SOUTH KOREA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)            270

TABLE 308            SOUTH KOREA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,

BY TYPE, 2023–2030 (USD MILLION)         270

TABLE 309            SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       271

TABLE 310            SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       271

TABLE 311            SOUTH KOREA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       272

TABLE 312            SOUTH KOREA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            272

TABLE 313            SOUTH KOREA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            273

TABLE 314            SOUTH KOREA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            273

TABLE 315            SOUTH KOREA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)            273

TABLE 316            SOUTH KOREA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            274

TABLE 317            SOUTH KOREA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            274

TABLE 318            SOUTH KOREA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            274

TABLE 319            SOUTH KOREA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)                275

TABLE 320            AUSTRALIA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     275

TABLE 321            AUSTRALIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)                 276

TABLE 322            AUSTRALIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            276

TABLE 323            AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)            277

TABLE 324            AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)            277

TABLE 325            AUSTRALIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       278

TABLE 326            AUSTRALIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 327            AUSTRALIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 328            AUSTRALIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            279

TABLE 329            AUSTRALIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)                 279

TABLE 330            AUSTRALIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                279

TABLE 331            AUSTRALIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            280

TABLE 332            AUSTRALIA: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              280

TABLE 333            AUSTRALIA: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)                281

TABLE 334            REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            281

TABLE 335            REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,

BY TYPE, 2023–2030 (USD MILLION)         282

TABLE 336            REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 282

TABLE 337            REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       283

TABLE 338            REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       283

TABLE 339            REST OF ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                284

TABLE 340            REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)                 284

TABLE 341            REST OF ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 285

TABLE 342            REST OF ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            285

TABLE 343            REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)            285

TABLE 344            REST OF ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            286

TABLE 345            REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)                 286

TABLE 346            REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            287

TABLE 347            REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            287

TABLE 348            LATIN AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     288

TABLE 349            LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     289

TABLE 350            LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)            289

TABLE 351            LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            290

TABLE 352            LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       290

TABLE 353            LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       291

TABLE 354            LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                291

TABLE 355            LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)                 291

TABLE 356            LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 357            LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 358            LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)            292

TABLE 359            LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            293

TABLE 360            LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)                 293

TABLE 361            LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            293

TABLE 362            LATIN AMERICA: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            294

TABLE 363            BRAZIL: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            294

TABLE 364            BRAZIL: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)          295

TABLE 365            BRAZIL: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 295

TABLE 366            BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         296

TABLE 367            BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    296

TABLE 368            BRAZIL: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       297

TABLE 369            BRAZIL: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 370            BRAZIL: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 371            BRAZIL: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 372            BRAZIL: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 373            BRAZIL: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                299

TABLE 374            BRAZIL: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            299

TABLE 375            BRAZIL: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              299

TABLE 376            BRAZIL: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            300

TABLE 377            MEXICO: BIOSURGERY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            300

TABLE 378            MEXICO: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,

2023–2030 (USD MILLION)            301

TABLE 379            MEXICO: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)                 301

TABLE 380            MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         302

TABLE 381            MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,

BY ORIGIN, 2023–2030 (USD MILLION)    302

TABLE 382            MEXICO: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       303

TABLE 383            MEXICO: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,

2023–2030 (USD MILLION)            303

TABLE 384            MEXICO: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            303

TABLE 385            MEXICO: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            304

TABLE 386            MEXICO: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,

2023–2030 (USD MILLION)            304

TABLE 387            MEXICO: BIOLOGICAL MESHES MARKET, BY TYPE, 2023–2030 (USD MILLION)                304

TABLE 388            MEXICO: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,

2023–2030 (USD MILLION)            305

TABLE 389            MEXICO: BIOSURGERY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              305

TABLE 390            MEXICO: BIOSURGERY MARKET, BY END USER, 2023–2030 (USD MILLION)            306

TABLE 391            REST OF LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            306

TABLE 392            REST OF LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 307

TABLE 393            REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            307

TABLE 394            REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)     308

TABLE 395            REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)                 308

TABLE 396            REST OF LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                309

TABLE 397            REST OF LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS,

BY TYPE, 2023–2030 (USD MILLION)         309

TABLE 398            REST OF LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)            310

TABLE 399            REST OF LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 310

TABLE 400            REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 310

TABLE 401            REST OF LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            311

TABLE 402            REST OF LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS,

BY TYPE, 2023–2030 (USD MILLION)         311

TABLE 403            REST OF LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            312

TABLE 404            REST OF LATIN AMERICA: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            312

TABLE 405            MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY REGION,

2023–2030 (USD MILLION)            313

TABLE 406            MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            314

TABLE 407            MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)            314

TABLE 408            MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION) 315

TABLE 409            MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)     315

TABLE 410            MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)                 316

TABLE 411            MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                316

TABLE 412            MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS,

BY TYPE, 2023–2030 (USD MILLION)         316

TABLE 413            MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023–2030 (USD MILLION)            317

TABLE 414            MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 415            MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION)            317

TABLE 416            MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 417            MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS,

BY TYPE, 2023–2030 (USD MILLION)         318

TABLE 418            MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            319

TABLE 419            MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            319

TABLE 420            GCC COUNTRIES: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            320

TABLE 421            GCC COUNTRIES: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION)            320

TABLE 422            GCC COUNTRIES: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            321

TABLE 423            GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)       321

TABLE 424            GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)       322

TABLE 425            GCC COUNTRIES: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)                322

TABLE 426            GCC COUNTRIES: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)                 322

TABLE 427            GCC COUNTRIES: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            323

TABLE 428            GCC COUNTRIES: NATURAL ADHESION BARRIERS MARKET, BY TYPE,

2023–2030 (USD MILLION)            323

TABLE 429            GCC COUNTRIES: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,

BY TYPE, 2023–2030 (USD MILLION)         323

TABLE 430            GCC COUNTRIES: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            324

TABLE 431            GCC COUNTRIES: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)                 324

TABLE 432            GCC COUNTRIES: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            324

TABLE 433            GCC COUNTRIES: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            325

TABLE 434            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            325

TABLE 435            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023–2030 (USD MILLION) 326

TABLE 436            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023–2030 (USD MILLION)            326

TABLE 437            REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)     327

TABLE 438            REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023–2030 (USD MILLION)                 327

TABLE 439            REST OF MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023–2030 (USD MILLION)         328

TABLE 440            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023–2030 (USD MILLION)            328

TABLE 441            REST OF MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         329

TABLE 442            REST OF MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         329

TABLE 443            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023–2030 (USD MILLION) 329

TABLE 444            REST OF MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE,

2023–2030 (USD MILLION)            330

TABLE 445            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023–2030 (USD MILLION)            330

TABLE 446            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            331

TABLE 447            REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER,

2023–2030 (USD MILLION)            331

TABLE 448            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSURGERY MARKET          332

TABLE 449            BIOSURGERY MARKET: DEGREE OF COMPETITION 335

TABLE 450            BIOSURGERY MARKET: REGION FOOTPRINT                 339

TABLE 451            BIOSURGERY MARKET: PRODUCT FOOTPRINT                 340

TABLE 452            BIOSURGERY MARKET: APPLICATION FOOTPRINT       341

TABLE 453            BIOSURGERY MARKET: END-USER FOOTPRINT                 342

TABLE 454            BIOSURGERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS             345

TABLE 455            BIOSURGERY MARKET: COMPETITIVE BENCHMARKING OF KEY

STARTUPS/SME PLAYERS, BY PRODUCT AND REGION   346

TABLE 456            BIOSURGERY MARKET: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–JUNE 2025              348

TABLE 457            BIOSURGERY MARKET: DEALS, JANUARY 2022–JUNE 2025             349

TABLE 458            BAXTER: COMPANY OVERVIEW 350

TABLE 459            BAXTER: PRODUCTS OFFERED 351

TABLE 460            B BRAUN SE: COMPANY OVERVIEW         354

TABLE 461            B BRAUN SE: PRODUCTS OFFERED          355

TABLE 462            BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW   357

TABLE 463            BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED    358

TABLE 464            JOHNSON & JOHNSON: COMPANY OVERVIEW                 361

TABLE 465            JOHNSON & JOHNSON: PRODUCTS OFFERED                 362

TABLE 466            MEDTRONIC: COMPANY OVERVIEW       365

TABLE 467            MEDTRONIC: PRODUCTS OFFERED        366

TABLE 468            INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW   369

TABLE 469            INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED    370

TABLE 470            COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY OVERVIEW  372

TABLE 471            COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): PRODUCTS OFFERED   373

TABLE 472            HEMOSTASIS, LLC: COMPANY OVERVIEW                 374

TABLE 473            HEMOSTASIS, LLC: PRODUCTS OFFERED                 374

TABLE 474            PFIZER INC.: COMPANY OVERVIEW         375

TABLE 475            PFIZER INC.: PRODUCTS OFFERED          376

TABLE 476            STRYKER: COMPANY OVERVIEW               377

TABLE 477            STRYKER: PRODUCTS OFFERED                378

TABLE 478            ARTIVION, INC.: COMPANY OVERVIEW 380

TABLE 479            ARTIVION, INC.: PRODUCTS OFFERED  381

TABLE 480            ZIMMER BIOMET: COMPANY OVERVIEW                 383

TABLE 481            ZIMMER BIOMET: PRODUCTS OFFERED                 384

TABLE 482            ZIMMER BIOMET: DEALS, JANUARY 2022–JUNE 2025        385

TABLE 483            KUROS BIOSCIENCES: COMPANY OVERVIEW                 386

TABLE 484            KUROS BIOSCIENCES: PRODUCTS OFFERED                 387

TABLE 485            KUROS BIOSCIENCES: PRODUCT APPROVALS, JANUARY 2021–JUNE 2025              387

TABLE 486            KUROS BIOSCIENCES: DEALS, JANUARY 2022–JUNE 2025             388

TABLE 487            ORTHOFIX MEDICAL INC.: COMPANY OVERVIEW          389

TABLE 488            ORTHOFIX MEDICAL INC.: PRODUCTS OFFERED             390

TABLE 489            ORTHOFIX MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025     391

TABLE 490            ORTHOFIX MEDICAL INC.: DEALS, JANUARY 2022–JUNE 2025  391

TABLE 491            SMITH & NEPHEW: COMPANY OVERVIEW                 392

TABLE 492            SMITH & NEPHEW: PRODUCTS OFFERED                 393

TABLE 493            TISSUE REGENIX: COMPANY OVERVIEW                 394

TABLE 494            BETATECH MEDICAL: COMPANY OVERVIEW                 395

TABLE 495            MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW          396

TABLE 496            GLOBUS MEDICAL: COMPANY OVERVIEW                 397

TABLE 497            SAMYANG HOLDINGS CORPORATION: COMPANY OVERVIEW   398

TABLE 498            AROA BIOSURGERY LIMITED: COMPANY OVERVIEW          399

TABLE 499            MEYER-HAAKE GMBH: COMPANY OVERVIEW                 400

TABLE 500            ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW   401

TABLE 501            BIOCER ENTWICKLUNGS-GMBH: COMPANY OVERVIEW          402

TABLE 502            WILTROM: COMPANY OVERVIEW            403

LIST OF FIGURES

FIGURE 1              BIOSURGERY MARKET SEGMENTATION & REGIONAL SCOPE            37

FIGURE 2              BIOSURGERY MARKET: YEARS CONSIDERED                 39

FIGURE 3              BIOSURGERY MARKET: RESEARCH DESIGN                 42

FIGURE 4              BIOSURGERY MARKET: KEY DATA FROM SECONDARY SOURCES  44

FIGURE 5              BIOSURGERY MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES) 45

FIGURE 6              BIOSURGERY MARKET: KEY DATA FROM PRIMARY SOURCES         46

FIGURE 7              BIOSURGERY MARKET: KEY INDUSTRY INSIGHTS            47

FIGURE 8              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION  47

FIGURE 9              BIOSURGERY MARKET SIZE ESTIMATION (REVENUE SHARE ANALYSIS)     48

FIGURE 10            BIOSURGERY MARKET: TOP-DOWN APPROACH                 49

FIGURE 11            IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES (2025–2030)  50

FIGURE 12            BIOSURGERY MARKET: CAGR PROJECTIONS                 50

FIGURE 13            BIOSURGERY MARKET: DATA TRIANGULATION METHODOLOGY              52

FIGURE 14            BIOSURGERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)       55

FIGURE 15            BIOSURGERY MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)                56

FIGURE 16            BIOSURGERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)       57

FIGURE 17            BIOSURGERY MARKET: REGIONAL SNAPSHOT                 58

FIGURE 18            RISING SURGICAL VOLUMES AND INCREASING FOCUS ON MEDICAL TOURISM TO DRIVE MARKET         59

FIGURE 19            US AND HOSPITALS SEGMENT COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024    60

FIGURE 20            INDIA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 61

FIGURE 21            ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2030              61

FIGURE 22            EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD    62

FIGURE 23            BIOSURGERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES     63

FIGURE 24            BIOSURGERY MARKET: VALUE CHAIN ANALYSIS                 70

FIGURE 25            BIOSURGERY MARKET: ECOSYSTEM ANALYSIS                 70

FIGURE 26            BIOSURGERY MARKET: SUPPLY CHAIN ANALYSIS            71

FIGURE 27            BIOSURGERY MARKET: PORTER’S FIVE FORCES ANALYSIS            74

FIGURE 28            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS

OF TOP THREE BIOSURGERY PRODUCTS             76

FIGURE 29            KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS         77

FIGURE 30            CANADA: CLASS III MEDICAL DEVICE APPROVAL PROCESS      81

FIGURE 31            TOP 10 COMPANIES WITH HIGHEST NUMBER OF PATENTS APPLIED/PUBLISHED (JANUARY 2014–JUNE 2025)                 83

FIGURE 32            TOP APPLICANT COUNTRIES/REGIONS FOR BIOSURGERY PATENTS

(JANUARY 2014− MAY 2025)         84

FIGURE 33            ADJACENT MARKET ANALYSIS: ADHESION BARRIERS MARKET (MARKET OVERVIEW)            87

FIGURE 34            BIOSURGERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS      89

FIGURE 35            BIOSURGERY MARKET: FUNDING AND NUMBER OF DEALS,

2019–2023 (USD MILLION)            89

FIGURE 36            KEY FEATURES OF AI/GEN AI IN BIOSURGERY MARKET               91

FIGURE 37            BIOSURGERY MARKET: GEOGRAPHIC SNAPSHOT          181

FIGURE 38            NORTH AMERICA: BIOSURGERY MARKET SNAPSHOT          183

FIGURE 39            ASIA PACIFIC: BIOSURGERY MARKET SNAPSHOT          244

FIGURE 40            REVENUE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2020–2024)           334

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOSURGERY MARKET (2024)      335

FIGURE 42            BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         337

FIGURE 43            BIOSURGERY MARKET: COMPANY FOOTPRINT                 338

FIGURE 44            BIOSURGERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 344

FIGURE 45            EV/EBITDA OF KEY VENDORS   347

FIGURE 46            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                347

FIGURE 47            BIOSURGERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS            348

FIGURE 48            BAXTER: COMPANY SNAPSHOT                 351

FIGURE 49            B BRAUN SE: COMPANY SNAPSHOT        355

FIGURE 50            BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT   358

FIGURE 51            JOHNSON & JOHNSON: COMPANY SNAPSHOT                 362

FIGURE 52            MEDTRONIC: COMPANY SNAPSHOT      366

FIGURE 53            INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT   370

FIGURE 54            COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY SNAPSHOT  373

FIGURE 55            PFIZER INC.: COMPANY SNAPSHOT         376

FIGURE 56            STRYKER: COMPANY SNAPSHOT              378

FIGURE 57            ARTIVION, INC.: COMPANY SNAPSHOT 381

FIGURE 58            ZIMMER BIOMET: COMPANY SNAPSHOT                 384

FIGURE 59            KUROS BIOSCIENCES: COMPANY SNAPSHOT                 386

FIGURE 60            ORTHOFIX MEDICAL INC.: COMPANY SNAPSHOT          390

FIGURE 61            SMITH & NEPHEW: COMPANY SNAPSHOT                 393

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧